

# WÅ,adysÅ,awa Anna Daniel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2982130/publications.pdf>

Version: 2024-02-01

93  
papers

2,183  
citations

218381

26  
h-index

276539

41  
g-index

93  
all docs

93  
docs citations

93  
times ranked

2386  
citing authors

#	ARTICLE	IF	CITATIONS
1	The relative contribution of human cytochrome P450 isoforms to the four caffeine oxidation pathways: An in vitro comparative study with cDNA-expressed P450s including CYP2C isoforms. <i>Biochemical Pharmacology</i> , 2008, 76, 543-551.	2.0	239
2	Mechanisms of cellular distribution of psychotropic drugs. Significance for drug action and interactions. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003, 27, 65-73.	2.5	81
3	Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat. <i>Pharmacological Reports</i> , 2008, 60, 789-97.	1.5	77
4	Cytochrome P450 mediates dopamine formation in the brain <i>in vivo</i> . <i>Journal of Neurochemistry</i> , 2011, 118, 806-815.	2.1	70
5	CHARACTERIZATION OF HUMAN CYTOCHROME P450 ENZYMES INVOLVED IN THE METABOLISM OF THE PIPERIDINE-TYPE PHENOTHIAZINE NEUROLEPTIC THIORIDAZINE. <i>Drug Metabolism and Disposition</i> , 2006, 34, 471-476.	1.7	58
6	Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver – A comparison with other phenothiazines. <i>Biochemical Pharmacology</i> , 2010, 80, 1252-1259.	2.0	58
7	The ability of cytochrome P450 2D isoforms to synthesize dopamine in the brain: An in vitro study. <i>European Journal of Pharmacology</i> , 2010, 626, 171-178.	1.7	56
8	Intracellular distribution of psychotropic drugs in the grey and white matter of the brain: the role of lysosomal trapping. <i>British Journal of Pharmacology</i> , 2001, 134, 807-814.	2.7	49
9	Contribution of human cytochrome P-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. <i>British Journal of Pharmacology</i> , 2003, 138, 1465-1474.	2.7	49
10	Regulation of liver cytochrome P450 by activation of brain dopaminergic system: Physiological and pharmacological implications. <i>Biochemical Pharmacology</i> , 2008, 76, 258-267.	2.0	49
11	Cytochrome P450 expression and regulation in the brain. <i>Drug Metabolism Reviews</i> , 2021, 53, 1-29.	1.5	49
12	The brain dopaminergic system as an important center regulating liver cytochrome P450 in the rat. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 631-645.	1.5	46
13	Lysosomal trapping as an important mechanism involved in the cellular distribution of perazine and in pharmacokinetic interaction with antidepressants. <i>European Neuropsychopharmacology</i> , 1999, 9, 483-491.	0.3	45
14	Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects. <i>European Journal of Medicinal Chemistry</i> , 2018, 145, 790-804.	2.6	43
15	Relative contribution of rat cytochrome P450 isoforms to the metabolism of caffeine: The pathway and concentration dependence. <i>Biochemical Pharmacology</i> , 2008, 75, 1538-1549.	2.0	42
16	N1-Azinylsulfonyl-1H-indoles: 5-HT <sub>6</sub> Receptor Antagonists with Procognitive and Antidepressant-Like Properties. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 618-622.	1.3	42
17	The Regulation of Liver Cytochrome P450 by the Brain Dopaminergic System. <i>Current Drug Metabolism</i> , 2007, 8, 631-638.	0.7	41
18	The effect of tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs) and newer antidepressant drugs on the activity and level of rat CYP3A. <i>European Neuropsychopharmacology</i> , 2006, 16, 178-186.	0.3	38

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants. <i>British Journal of Pharmacology</i> , 2000, 131, 287-295.	2.7	36
20	The engagement of brain cytochrome P450 in the metabolism of endogenous neuroactive substrates: a possible role in mental disorders. <i>Drug Metabolism Reviews</i> , 2018, 50, 415-429.	1.5	35
21	The influence of long-term treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2005, 1, 203-217.	1.5	34
22	Direct and indirect interactions between antidepressant drugs and CYP2C6 in the rat liver during long-term treatment. <i>European Neuropsychopharmacology</i> , 2006, 16, 580-587.	0.3	34
23	The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. <i>European Neuropsychopharmacology</i> , 2004, 14, 199-208.	0.3	32
24	The catalytic competence of cytochrome P450 in the synthesis of serotonin from 5-methoxytryptamine in the brain: An in vitro study. <i>Pharmacological Research</i> , 2013, 67, 53-59.	3.1	32
25	The cytochrome P450 2Dâ€mediated formation of serotonin from 5â€methoxytryptamine in the brain <i>in vivo</i>: a microdialysis study. <i>Journal of Neurochemistry</i> , 2015, 133, 83-92.	2.1	31
26	Cytochrome P450 is regulated by noradrenergic and serotonergic systems. <i>Pharmacological Research</i> , 2011, 64, 371-380.	3.1	28
27	Role of brain cytochrome P450 (CYP2D) in the metabolism of monoaminergic neurotransmitters. <i>Pharmacological Reports</i> , 2013, 65, 1519-1528.	1.5	27
28	Involvement of the paraventricular (PVN) and arcuate (ARC) nuclei of the hypothalamus in the central noradrenergic regulation of liver cytochrome P450. <i>Biochemical Pharmacology</i> , 2013, 86, 1614-1620.	2.0	27
29	Effect of classic and atypical neuroleptics on cytochrome P450 3A (CYP3A) in rat liver. <i>Pharmacological Reports</i> , 2012, 64, 1411-1418.	1.5	26
30	In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drugâ€drug interactions. <i>Pharmacological Reports</i> , 2020, 72, 612-621.	1.5	26
31	Inhibition and possible induction of rat CYP2D after short- and long-term treatment with antidepressants. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 54, 1545-1552.	1.2	25
32	The effect of psychotropic drugs on cytochrome P450 2D (CYP2D) in rat brain. <i>European Journal of Pharmacology</i> , 2011, 651, 51-58.	1.7	24
33	Melatonin Supports CYP2D-Mediated Serotonin Synthesis in the Brain. <i>Drug Metabolism and Disposition</i> , 2016, 44, 445-452.	1.7	24
34	The role of brain noradrenergic system in the regulation of liver cytochrome P450 expression. <i>Biochemical Pharmacology</i> , 2013, 86, 800-807.	2.0	21
35	Effect of antidepressant drugs on cytochrome P450 2C11 (CYP2C11) in rat liver. <i>Pharmacological Reports</i> , 2013, 65, 1247-1255.	1.5	21
36	Damage to the Brain Serotonergic System Increases the Expression of Liver Cytochrome P450. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1345-1352.	1.7	21

#	ARTICLE	IF	CITATIONS
37	Effect of selected antidepressant drugs on cytochrome P450 2B (CYP2B) in rat liver. An in vitro and in vivo study. <i>Pharmacological Reports</i> , 2008, 60, 957-65.	1.5	20
38	The activity of brain and liver cytochrome P450 2D (CYP2D) is differently affected by antidepressants in the chronic mild stress (CMS) model of depression in the rat. <i>Biochemical Pharmacology</i> , 2018, 156, 398-405.	2.0	19
39	Stimulation of noradrenergic transmission by reboxetine is beneficial for a mouse model of progressive parkinsonism. <i>Scientific Reports</i> , 2019, 9, 5262.	1.6	19
40	Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo – possible involvement of different mechanisms. <i>European Neuropsychopharmacology</i> , 2005, 15, 103-110.	0.3	18
41	The reverse role of the hypothalamic paraventricular (PVN) and arcuate (ARC) nuclei in the central serotonergic regulation of the liver cytochrome P450 isoform CYP2C11. <i>Biochemical Pharmacology</i> , 2016, 112, 82-89.	2.0	18
42	Activation of brain serotonergic system by repeated intracerebral administration of 5-hydroxytryptophan (5-HTP) decreases the expression and activity of liver cytochrome P450. <i>Biochemical Pharmacology</i> , 2016, 99, 113-122.	2.0	18
43	Perazine at therapeutic drug concentrations inhibits human cytochrome P450 isoenzyme 1A2 (CYP1A2) and caffeine metabolism – an in vitro study. <i>Pharmacological Reports</i> , 2009, 61, 851-858.	1.5	17
44	The cytochrome P450-catalyzed metabolism of levomepromazine: a phenothiazine neuroleptic with a wide spectrum of clinical application. <i>Biochemical Pharmacology</i> , 2014, 90, 188-195.	2.0	17
45	The contribution of cytochrome P-450 isoenzymes to the metabolism of phenothiazine neuroleptics. <i>European Neuropsychopharmacology</i> , 2002, 12, 371-377.	0.3	15
46	The role of the dorsal noradrenergic pathway of the brain (locus coeruleus) in the regulation of liver cytochrome P450 activity. <i>European Journal of Pharmacology</i> , 2015, 751, 34-41.	1.7	15
47	Thioridazine-fluoxetine interaction at the level of the distribution process in vivo. <i>Polish Journal of Pharmacology</i> , 2002, 54, 647-54.	0.3	15
48	The influence of selective serotonin reuptake inhibitors on the plasma and brain pharmacokinetics of the simplest phenothiazine neuroleptic promazine in the rat. <i>European Neuropsychopharmacology</i> , 1999, 9, 337-344.	0.3	14
49	Disposition of 1,2,3,4-tetrahydroisoquinoline in the brain of male Wistar and Dark Agouti rats. <i>Brain Research</i> , 2004, 996, 168-179.	1.1	14
50	Simultaneous alterations of brain and plasma serotonin concentrations and liver cytochrome P450 in rats fed on a tryptophan-free diet. <i>Pharmacological Research</i> , 2012, 66, 292-299.	3.1	14
51	The mechanisms of interactions of psychotropic drugs with liver and brain cytochrome P450 and their significance for drug effect and drug-drug interactions. <i>Biochemical Pharmacology</i> , 2022, 199, 115006.	2.0	14
52	Different Effects of Amitriptyline and Imipramine on the Pharmacokinetics and Metabolism of Perazine in Rats. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 52, 1473-1481.	1.2	13
53	The regulation of liver cytochrome P450 expression and activity by the brain serotonergic system in different experimental models. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 413-424.	1.5	13
54	Effect of cytochrome P450 (CYP) inducers on caffeine metabolism in the rat. <i>Pharmacological Reports</i> , 2007, 59, 296-305.	1.5	13

#	ARTICLE	IF	CITATIONS
55	Disruption of glucocorticoid receptors in the noradrenergic system leads to BDNF up-regulation and altered serotonergic transmission associated with a depressive-like phenotype in female GRDBHCre mice. <i>Pharmacology Biochemistry and Behavior</i> , 2015, 137, 69-77.	1.3	12
56	The Effect of Chronic Treatment with Lurasidone on Rat Liver Cytochrome P450 Expression and Activity in the Chronic Mild Stress Model of Depression. <i>Drug Metabolism and Disposition</i> , 2017, 45, 1336-1344.	1.7	12
57	Effect of short- and long-term treatment with antidepressant drugs on the activity of rat CYP2A in the liver. <i>Pharmacological Reports</i> , 2005, 57, 774-81.	1.5	12
58	The atypical neuroleptics iloperidone and lurasidone inhibit human cytochrome P450 enzymes in vitro. Evaluation of potential metabolic interactions. <i>Pharmacological Reports</i> , 2020, 72, 1685-1694.	1.5	11
59	The activity of cytochrome P450 CYP2B in rat liver during neuroleptic treatment. <i>Pharmacological Reports</i> , 2007, 59, 606-12.	1.5	11
60	Effect of neuroleptics on cytochrome P450 2C11 (CYP2C11) in rat liver. <i>Pharmacological Reports</i> , 2011, 63, 1491-1499.	1.5	10
61	The effect of ageing and cerebral serotonin deficit on the activity of cytochrome P450 2D (CYP2D) in the brain and liver of male rats. <i>Neurochemistry International</i> , 2020, 141, 104884.	1.9	10
62	The effect of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics and metabolism of perazine in the rat. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 53, 449-461.	1.2	9
63	Effects of low doses of intracerebroventricular 6-OHDA on the levels of monoaminergic neurotransmitters in rat brain structures. <i>Pharmacological Reports</i> , 2010, 62, 1225-1230.	1.5	9
64	Activation of 5-HT <sub>1A</sub> Receptors in the Hypothalamic Paraventricular Nuclei Negatively Regulates Cytochrome P450 Expression and Activity in Rat Liver. <i>Drug Metabolism and Disposition</i> , 2018, 46, 786-793.	1.7	9
65	Effect of chronic treatment with perazine on lipopolysaccharide-induced interleukin-1 $\beta$ levels in the rat brain. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2006, 373, 79-84.	1.4	8
66	Inhibition of human cytochrome P450 isoenzymes by a phenothiazine neuroleptic levomepromazine: An in vitro study. <i>Pharmacological Reports</i> , 2015, 67, 1178-1182.	1.5	8
67	Asenapine and iloperidone decrease the expression of major cytochrome P450 enzymes CYP1A2 and CYP3A4 in human hepatocytes. A significance for drug-drug interactions during combined therapy. <i>Toxicology and Applied Pharmacology</i> , 2020, 406, 115239.	1.3	8
68	Cytochrome P450 2D (CYP2D) enzyme dysfunction associated with aging and serotonin deficiency in the brain and liver of female Dark Agouti rats. <i>Neurochemistry International</i> , 2022, 152, 105223.	1.9	8
69	Effects of classic and newer antidepressants on the oxidation pathways of caffeine in rat liver. In vitro study. <i>Polish Journal of Pharmacology</i> , 2003, 55, 1045-53.	0.3	8
70	Interactions between neuroleptics and CYP2C6 in rat liver--in vitro and ex vivo study. <i>Pharmacological Reports</i> , 2005, 57, 872-7.	1.5	8
71	Identification of factors mediating the effect of the brain dopaminergic system on the expression of cytochrome P450 in the liver. <i>Pharmacological Reports</i> , 2008, 60, 966-71.	1.5	8
72	Serotonin Receptors of 5-HT <sub>2</sub> Type in the Hypothalamic Arcuate Nuclei Positively Regulate Liver Cytochrome P450 via Stimulation of the Growth Hormone-Releasing Hormone/Growth Hormone Hormonal Pathway. <i>Drug Metabolism and Disposition</i> , 2019, 47, 80-85.	1.7	7

#	ARTICLE	IF	CITATIONS
73	Effect of diethyldithiocarbamate (DDC) and ticlopidine on CYP1A2 activity and caffeine metabolism: an in vitro comparative study with human cDNA-expressed CYP1A2 and liver microsomes. <i>Pharmacological Reports</i> , 2009, 61, 1216-1220.	1.5	6
74	The effects of agomelatine and imipramine on liver cytochrome P450 during chronic mild stress (CMS) in the rat. <i>Pharmacological Reports</i> , 2020, 72, 1271-1287.	1.5	6
75	Levomepromazine and clozapine induce the main human cytochrome P450 drug metabolizing enzyme CYP3A4. <i>Pharmacological Reports</i> , 2021, 73, 303-308.	1.5	6
76	The Influence of Long-Term Treatment with Asenapine on Liver Cytochrome P450 Expression and Activity in the Rat. The Involvement of Different Mechanisms. <i>Pharmaceuticals</i> , 2021, 14, 629.	1.7	6
77	Perazine as a potent inhibitor of human CYP1A2 but not CYP3A4. <i>Polish Journal of Pharmacology</i> , 2002, 54, 407-10.	0.3	6
78	Influence of classic and atypical neuroleptics on caffeine oxidation in rat liver microsomes. <i>Polish Journal of Pharmacology</i> , 2003, 55, 1055-61.	0.3	6
79	Direct effects of neuroleptics on the activity of CYP2A in the liver of rats. <i>Pharmacological Reports</i> , 2005, 57, 867-71.	1.5	6
80	Influence of antidepressant drugs on chlorpromazine metabolism in human liver -an in vitro study. <i>Pharmacological Reports</i> , 2010, 62, 1062-1069.	1.5	5
81	Chronic treatment with asenapine affects cytochrome P450 2D (CYP2D) in rat brain and liver. Pharmacological aspects. <i>Neurochemistry International</i> , 2021, 151, 105209.	1.9	5
82	Caffeine metabolism during prolonged treatment of rats with antidepressant drugs. <i>Pharmacological Reports</i> , 2007, 59, 727-33.	1.5	5
83	Long-Term Treatment with Atypical Antipsychotic Iloperidone Modulates Cytochrome P450 2D (CYP2D) Expression and Activity in the Liver and Brain via Different Mechanisms. <i>Cells</i> , 2021, 10, 3472.	1.8	5
84	The influence of amitriptyline and carbamazepine on levomepromazine metabolism in human liver: An in vitro study. <i>Pharmacological Reports</i> , 2014, 66, 1122-1126.	1.5	4
85	Stimulation of 5-HT <sub>2C</sub> serotonin receptor subtype in the hypothalamic arcuate nuclei (ARC) increases the cytochrome P450 activity in the liver. <i>Pharmacological Reports</i> , 2019, 71, 1210-1212.	1.5	4
86	The Effect of Chronic Iloperidone Treatment on Cytochrome P450 Expression and Activity in the Rat Liver: Involvement of Neuroendocrine Mechanisms. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8447.	1.8	4
87	Autoinduction of the metabolism of phenothiazine neuroleptics in a primary culture of human hepatocytes. <i>Pharmacological Reports</i> , 2012, 64, 1578-1583.	1.5	3
88	Gender-dependent activity of CYP3A is indirectly modified by GR in the noradrenergic system. <i>Pharmacological Reports</i> , 2013, 65, 1431-1434.	1.5	3
89	Desipramine administered chronically inhibits lipopolysaccharide-stimulated production of IL-1 $\beta$ in the brain and plasma of rats. <i>Cytokine</i> , 2016, 80, 26-34.	1.4	3
90	Treatment with dopamine $\beta$ -hydroxylase (DBH) inhibitors prevents morphine use and relapse-like behavior in rats. <i>Pharmacological Reports</i> , 2021, 73, 1694-1711.	1.5	3

#	ARTICLE	IF	CITATIONS
91	The Selective NMDA Receptor GluN2B Subunit Antagonist CP-101,606 with Antidepressant Properties Modulates Cytochrome P450 Expression in the Liver. <i>Pharmaceutics</i> , 2021, 13, 1643.	2.0	3
92	Effects of chronic treatment with classic and newer antidepressants and neuroleptics on the activity and level of CYP2D in the rat brain. <i>Polish Journal of Pharmacology</i> , 2004, 56, 857-62.	0.3	2
93	Effect of mirtazapine on the CYP2D activity in the primary culture of rat hepatocytes. <i>Pharmacological Reports</i> , 2006, 58, 979-84.	1.5	2